Key Takeaways:
- DexForce Technology explores Hong Kong IPO that could raise several hundred million USD
- Series B raised RMB1 billion at a valuation exceeding RMB10 billion
- Investors include Shenzhen Capital Group and ICBC Capital
返回
DexForce weighs HK IPO to raise several hundred million USD
Chinese humanoid robot maker DexForce Technology is exploring a Hong Kong IPO that could raise several hundred million USD, Bloomberg reported.
The company has held preliminary talks with potential advisers, according to people familiar with the matter cited by Bloomberg.
Founded in 2021, DexForce manufactures an integrated portfolio of software and hardware products, including the EmbodiChain embodied intelligence development platform, the DexForce W1 Pro general-purpose humanoid robot, and the DexSense pure-vision sensor. The company recently raised RMB1 billion in a Series B funding round at a valuation exceeding RMB10 billion. Investors included Shenzhen Capital Group and ICBC Capital, the investment arm of Industrial and Commercial Bank of China (01398.HK), which traded down 3.4 percent on the day.
A successful listing would give DexForce access to international capital markets as China's humanoid robot sector draws global investor attention. The company's valuation of more than RMB10 billion places it among the most valuable startups in China's embodied intelligence space, competing with listed peers such as UBTech Robotics and privately held Unitree Robotics.
Hong Kong has become the preferred listing venue for Chinese technology companies seeking international capital. Several robotics and AI firms have completed or announced HK listings in recent years, drawn by the city's proximity to mainland investors and its global market infrastructure.
DexForce's product portfolio spans the full embodied intelligence stack, from its EmbodiChain development platform to the W1 Pro humanoid robot and DexSense vision sensors. The Series B round, completed with backing from state-linked investors, reflects the strategic importance Beijing places on advanced robotics as a national priority.
The W1 Pro humanoid robot targets general-purpose applications across manufacturing, logistics, and service industries. The EmbodiChain platform provides developers with tools to build and deploy embodied intelligence applications, while DexSense sensors enable vision-based perception for robotic systems.
China's humanoid robot market is projected to grow rapidly over the next decade, driven by government support and industrial automation demand. The country's robotics sector has attracted significant venture capital funding, with multiple startups achieving unicorn status in recent years.
The IPO would test institutional appetite for Chinese robotics companies as global investors weigh the sector's growth potential against geopolitical risks. Investors will watch for the company's filing details, including offer price and listing timeline, in the coming months.
This article is for informational purposes only and does not constitute investment advice.
